Zynyz Plus Chemo Combo Improves Survival in Recurrent/Metastatic SCAC

September 14th 2024, 11:00pm

By Kyle Doherty

Adding Zynyz to carboplatin and paclitaxel prolonged survival without progression in chemotherapy-naive recurrent or metastatic squamous cell carcinoma of the anal canal.

TILs May Predict Survival in Early HER2-Positive Breast Cancer Treated With Herceptin

September 14th 2024, 10:22pm

By Darlene Dobkowski, MA

High TILs may predict which patients with early HER2-positive breast cancer may have a reduced risk for disease relapse or death with Herceptin treatment.

Lenvima Regimen Offers Benefits in Intermediate Stage Liver Cancer

September 14th 2024, 9:51pm

By Ashley Chan

Patients with intermediate-stage liver cancer may benefit from receiving a Lenvima-Keytruda combination with transarterial chemoembolization.

Survival, Progression Improves With Xofigo Plus Xtandi for Certain Patients With Prostate Cancer

September 14th 2024, 9:40pm

By Megan Hollasch

Patients with metastatic, castration-resistant prostate cancer saw significant benefits from the combination of Xofigo and Xtandi.

Keytruda Plus Chemoradiotherapy May Represent New Standard of Care in Cervical Cancer Subset

September 14th 2024, 9:11pm

By Kristi Rosa

Patients with previously untreated, high-risk locally advanced cervical cancer experienced improved survival when treated with Keytruda plus chemoradiotherapy.

Postsurgical Keytruda Plus Chemo May Benefit Patients With dMMR Endometrial Cancer

September 14th 2024, 8:30pm

By Gina Mauro

Study findings were mixed regarding the postsurgical combination of Keytruda and chemotherapy with or without radiation among patients with high-risk endometrial cancer.

Rybrevant Plus Chemo Results in Superior Outcomes in EGFR-Mutant Advanced NSCLC

September 14th 2024, 4:34pm

By Darlene Dobkowski, MA

Rybrevant plus chemotherapy improved overall survival versus chemo alone in EGFR-mutant advanced non-small cell lung cancer after disease progression.

Enhertu Demonstrates Overall, Intracranial Activity in HER2-Positive Breast Cancer

September 13th 2024, 10:00pm

By Kristi Rosa

Patients with HER2-positive breast cancer benefitted from treatment with Enhertu regardless of brain metastasis.

Welireg Shows Stable Survival Benefits Over Afinitor in Kidney Cancer

September 13th 2024, 9:00pm

By Caroline Seymour

Among patients with previously treated advanced clear cell renal cell carcinoma (RCC) Welireg continued to show some benefits, though not to overall survival.

Imfinzi After Primary Treatment Does Not Improve Disease-Free Survival in PD-L1-Positive NSCLC

September 13th 2024, 7:00pm

By Ariana Pelosci

Patients with NSCLC did not see a disease-free survival benefit with Imfinzi after surgery compared with taking a placebo.

A Lesson About Mindset I Learned Overcoming a Less than 10% Survival Rate

September 13th 2024, 5:00pm

By Steve Rubin

Looking back at my experience with osteosarcoma, I realized that managing the mental game was half the battle, especially with so much negativity.

Princess Kate Finishes Chemo, E Street Band Member Announces Diagnosis and More

September 13th 2024, 3:00pm

By Alex Biese

From Princess Kate entering ‘a new phase of recovery’ to a Rock and Roll Hall of Famer’s blood cancer announcement, here’s what’s happening in the cancer space this week.

Fixed-Duration vs Continuous CLL Therapy: Balancing Efficacy, Quality of Life, and Costs

September 13th 2024, 2:54pm

The discussion will cover fixed-duration treatments vs continuous therapy for CLL and provide a brief overview of venetoclax-based regimens approved for 12 cycles with obinutuzumab and 24 cycles with rituximab.

CLL Treatment and Quality of Life: Patient Empowerment and Shared Decision-making

September 13th 2024, 2:52pm

The discussion will cover experiences with CLL treatment, focusing on key factors in treatment decisions, how care teams educate patients about options, strategies for discussing adverse events, and communicating adverse effects to the care team.

Steering the Treatment of Gynecologic Cancers With Biomarkers

September 13th 2024, 1:00pm

By Darlene Dobkowski, MA

Several drug classes, including immunotherapy, antibody-drug conjugates and PARP inhibitors have helped improve outcomes for gynecologic cancers.